Reversal of experimentally induced seizure activity in mice by glibenclamide

Background ATP sensitive potassium channels are widely distributed in central nervous system (CNS) and these channels could be the target in CNS disorders by their modulators. Purpose The present study was designed to investigate the anticonvulsant potential of glibenclamide on MES induced seizure and pentylenetetrazole induced seizure in mice. Methods Seizures were induced in 7 months albino mice with a single 12 mA intensity of 50 Hz stimulus for 0.2 s using electroconvulsiometer. Tonic flexion, tonic extension, clonic convulsion and mortality protection were recorded, 60 minutes after the oral administration of the vehicle (3% Tween 80), Standard (diazepam 3 mg/kg i.p.) and glibenclamide (5 mg/kg). In second model, seizures were induced with a single convulsive dose (80 mg/kg i.p) of pentylentetrazole (PTZ). Seizures were assessed in terms of onset of seizure, number of jerks, onset of tonic convulsion and clonic convulsions and mortality protection. The study was performed at antidiabetic dose of glibenclamide 5 mg/kg per oral. Results Glibenclamide (5 mg/kg p.o.) showed significant (p<0.05) protective activity in MES induced seizures and attenuated pentylenetetrazole-induced seizure activity in mice. The anticonvulsant action of glibenclamide was noticeable in this study. However, further studies are required to elucidate its full anticonvulsant potential. Conclusions Glibenclamide is able to exert protective effects in MES induced seizures and attenuates pentylenetetrazole induced seizure activity in mice.

[1]  C. Bever,et al.  Potassium channel blockers and openers as CNS neurologic therapeutic agents. , 2007, Recent patents on CNS drug discovery.

[2]  G. Kaczorowski,et al.  Potassium Channels as Targets for Therapeutic Intervention , 2005, Science's STKE.

[3]  H G Wieser,et al.  Commission on European Affairs: Appropriate Standards of Epilepsy Care Across Europe , 1997, Epilepsia.

[4]  A. Hofman,et al.  Maternal Use of Antiepileptic Drugs and the Risk of Major Congenital Malformations: A Joint European Prospective Study of Human Teratogenesis Associated with Maternal Epilepsy , 1997, Epilepsia.

[5]  D. Steiner,et al.  Pas de deux or more: the sulfonylurea receptor and K+ channels. , 1995, Science.

[6]  W. Löscher,et al.  The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models , 1991, Epilepsy Research.

[7]  A. E. Boyd Sulfonylurea Receptors, Ion Channels, and Fruit Flies , 1988, Diabetes.

[8]  M. Ticku,et al.  Involvement of a GABAergic mechanism in the anticonvulsant effect of pentobarbital against maximal electroshock-induced seizures in rats , 1985, Pharmacology Biochemistry and Behavior.

[9]  C. Cashin,et al.  AN APPARATUS FOR TESTING ANTICONVULSANT DRUGS BY ELECTROSHOCK SEIZURES IN MICE , 1962, The Journal of pharmacy and pharmacology.

[10]  J. W. Bastian,et al.  CNS drug specificity as determined by the mouse intravenous pentylenetetrazol technique. , 1959, The Journal of pharmacology and experimental therapeutics.